Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab

NCT07510724 · clinicaltrials.gov ↗

RECRUITING

Status

240

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Cancer (SCLC)
Non-Small Cell Lung Cancer (NSCLC)
Lung Cancer (Diagnosis)

Sponsor

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Collaborators

[object Object]